Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial

ABSTRACT:

SUBMITTER: Nielsen C 

PROVIDER: S-EPMC12945526 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature